FDA advisors back Sarepta's gene therapy; Layoffs, big and small; Gilead, Sobi fuel M&A fire; Endpoints 100; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
Beyond Sarepta’s closely watched gene therapy adcomm, there’s a good mix of fast-moving news and special reports where we take a step back for a deeper look in this week’s issue. You can always send us your thoughts by responding to this email.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.